^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    TP53 exon 5 mutation

    i
    Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1
    Entrez ID:
    7157
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over1year
    TP53 Exon 5 Mutation Indicates Poor Progression-Free Survival for Patients with Stage IV NSCLC. (PubMed, Front Biosci (Landmark Ed))
    TP53 mutation in exon 5 could independently predict poor PFS of patients with stage IV NSCLC after the first- line treatment. Moreover, mutations in TP53 exon 5 and LRP1B were associated with shorter PFS of such patients whether after first-line chemotherapy or targeted therapy, respectively. Thus, these patients should be given immunotherapy or immunochemotherapy.
    Journal • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • LRP1B (LDL Receptor Related Protein 1B) • FAT3 (FAT Atypical Cadherin 3)
    |
    TP53 mutation • EGFR mutation • BRAF mutation • ALK mutation • FAT3 mutation • TP53 exon 5 mutation
    2years
    A Tale of Concurrent Gene Mutations in EGFR and TP53 through a Next-Generation Sequencing Approach (AMP 2022)
    In the present study, exon 5 was the most common mutation site of TP53. EGFR resistance mutation T790M was found to be predominantly associated with TP53 exon 8 mutations. This group of patients who were treated with third-generation TKI, osimertinib, had progressive disease and/or succumbed.
    Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha)
    |
    TP53 mutation • EGFR mutation • PIK3CA mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • EGFR exon 20 insertion • EGFR exon 20 mutation • EGFR mutation + PIK3CA mutation • TP53 exon 5 mutation
    |
    Tagrisso (osimertinib)
    over3years
    TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib. (PubMed, Transl Oncol)
    Patients with TP53 mutations, especially in exons 6 and 7, had a lower response rate and shorter PFS and OS when treated with gefitinib. Moreover, TP53 exon 5 mutation divided TP53 mutations in disruptive and non-disruptive types.
    Clinical • Journal • Circulating tumor DNA
    |
    EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)
    |
    TP53 mutation • EGFR mutation • EGFR L858R • EGFR exon 19 mutation • TP53 exon 5 mutation
    |
    gefitinib